Display options
Cite
Hossein-Rashidi B, Khandzad B, Shahrokh-Tehraninejad E, et al. Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial. J Family Reprod Health. 2016;10(1):42-8
Hossein-Rashidi, B., Khandzad, B., Shahrokh-Tehraninejad, E., Bagheri, M., & Gorginzadeh, M. (2016). Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial. Journal of family & reproductive health, 10(1), 42-8.
Hossein-Rashidi, Batool, et al. "Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial." Journal of family & reproductive health vol. 10,1 (2016): 42-8.
Hossein-Rashidi B, Khandzad B, Shahrokh-Tehraninejad E, Bagheri M, Gorginzadeh M. Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial. J Family Reprod Health. 2016 Mar;10(1):42-8. PMID: 27385973; PMCID: PMC4930453.
Copy Download .nbib Format: NLM
Share it on

J Family Reprod Health. 2016 Mar;10(1):42-8.

Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial.

Journal of family & reproductive health

Batool Hossein-Rashidi, Bahareh Khandzad, Ensieh Shahrokh-Tehraninejad, Maryam Bagheri, Mansoureh Gorginzadeh

Affiliations

  1. Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  2. Tehran University of Medical Sciences, Tehran, Iran.

PMID: 27385973 PMCID: PMC4930453

Abstract

OBJECTIVE: Since there is still controversy regarding the best first-line choice for ovulation induction (OI) other than clomiphene citrate (CC) in infertile women diagnosed with polycystic ovary syndrome (PCOS), the aim of the present study was to compare recombinant human FSH with CC as the first course of OI in these women.

MATERIALS AND METHODS: In this pilot randomized controlled trial, 104 infertile women diagnosed with PCOS were randomized in two groups to receive either CC with the dose of 100mg per day from day 3 of a spontaneous or progestin-induced menstruation for 5 days or rFSH with the starting dose of 50 IU daily {and weekly dose increment of as low as 12.5 IU}, on the day4 of the cycle. They were assessed during a single OI course. The pregnancy rate (PR) and live birth rate (LBR) were the primary outcomes. The follicular response, endometrial thickness, cancellation of the cycles and ovarian hyper stimulation (OHSS) rate were the secondary outcomes.

RESULTS: Analyzing data of 96 patients using Chi(2) and Fischer's Exact test (44 in rFSH group and 52 in CC group), both PR and LBR were comparable in the two groups {13.6% vs. 9.6% and 11.4% vs. 9.6% respectively}, with the difference not to be significant (p > 0.05). No cases of OHSS or multiple gestations happened during the treatment course.

CONCLUSION: It seems that rFSH is as efficacious as CC while not with more complications for the first-line OI in infertile women with PCOS. However, due to the limitations of the present study including the small population and the single cycle of treatment, our results did not come out to prove this and more studies with larger study population are needed to compare the cumulative PR and LBR.

Keywords: Clomiphene Citrate; Ovulation Induction; Polycystic Ovary Syndrome; Recombinant FSH

References

  1. Semin Reprod Med. 2003 Feb;21(1):39-47 - PubMed
  2. Hum Reprod. 2008 Mar;23(3):462-77 - PubMed
  3. Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):261-74 - PubMed
  4. J Endocrinol Invest. 2015 Sep;38(9):1025-37 - PubMed
  5. Reprod Biomed Online. 2004 Oct;9(4):382-90 - PubMed
  6. J Assist Reprod Genet. 2013 Nov;30(11):1477-85 - PubMed
  7. Fertil Steril. 2010 May 1;93(7):2269-73 - PubMed
  8. Hum Reprod Update. 1999 Sep-Oct;5(5):493-9 - PubMed
  9. Curr Opin Obstet Gynecol. 2009 Dec;21(6):465-73 - PubMed
  10. Cochrane Database Syst Rev. 2001;(2):CD002121 - PubMed
  11. Fertil Steril. 2009 Apr;91(4 Suppl):1533-5 - PubMed
  12. Reprod Biomed Online. 2009 Apr;18(4):516-21 - PubMed
  13. BMJ. 2013 Feb 20;346:f650 - PubMed
  14. BMC Womens Health. 2013 Oct 25;13:42 - PubMed
  15. Iran J Reprod Med. 2015 Feb;13(2):61-70 - PubMed
  16. Hum Reprod. 2012 Feb;27(2):468-73 - PubMed
  17. Hum Reprod. 2001 Aug;16(8):1694-7 - PubMed
  18. Fertil Steril. 2004 Jan;81(1):19-25 - PubMed
  19. Minerva Endocrinol. 2015 Sep;40(3):195-212 - PubMed
  20. Hum Reprod Update. 2012 Sep-Oct;18(5):586-99 - PubMed
  21. Ann Endocrinol (Paris). 2010 May;71(3):225-7 - PubMed
  22. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD002249 - PubMed
  23. Hum Fertil (Camb). 2000;3(2):106-111 - PubMed

Publication Types